Welcome to our dedicated page for Microbot Medical SEC filings (Ticker: MBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Microbot Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Microbot Medical's regulatory disclosures and financial reporting.
Microbot Medical, Inc. is a pre-commercial, clinical-stage medical device company developing the LIBERTY® Endovascular Robotic Surgical System. As of June 30, 2025, the company held approximately $4.1 million in cash and $28.6 million in money market mutual funds (marketable securities), totaling about $32.7 million of cash and marketable securities and $33.1 million in total assets. Shareholders' equity rose to $30.4 million from $3.5 million at year-end 2024, primarily driven by equity financings completed in early 2025.
Microbot reported a net loss of $3.5 million for the quarter and $6.1 million for the six months ended June 30, 2025 (basic and diluted loss per share of $0.10 and $0.18, respectively). Operating cash used was $5.4 million for the six months, while financing activities provided $32.6 million of cash. The company remains pre-revenue, has an accumulated deficit of $97.0 million, notes continuing risks from Israeli regional instability, and states management believes available funds plus recent capital raises are sufficient to fund operations for more than twelve months from issuance of these statements.
Microbot Medical Inc. (Nasdaq: MBOT) filed a Form S-8 on 21 Jul 2025 to register an additional 3,791,019 common shares for issuance under its 2020 Omnibus Performance Award Plan. The pool was last expanded by 2,591,019 shares approved on 10 Jun 2025. The filing is made under General Instruction E and incorporates the company’s prior S-8 (File No. 333-250963).
The registration statement also includes a re-offer prospectus for up to 2,009,697 shares underlying options held by directors and officers that may be resold on a continuous basis under Rule 415. No proceeds will accrue to the company; any sales will be effected by the holders. With 39,991,652 shares outstanding, the newly registered shares equal roughly 9.5% potential dilution, while the re-offer covers about 5.0% of current float.
Corporate updates inside the prospectus note key milestones: 510(k) submitted for the fully disposable LIBERTY® Endovascular Robotic System (10 Dec 2024) with FDA clearance targeted for Q3 2025 and U.S. launch immediately thereafter; ISO 13485 certification obtained Aug 2024; CE-Mark expected 2H 2026. A $4.82 m ATM program (4.28 m shares) has been completed, and management states that ongoing regional conflicts have not yet produced material operational effects.